<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953472</url>
  </required_header>
  <id_info>
    <org_study_id>06-003032</org_study_id>
    <secondary_id>MC cardiorenal lab funds</secondary_id>
    <nct_id>NCT00953472</nct_id>
  </id_info>
  <brief_title>B-type Natriuretic Peptide (BNP) in Human Hypertension</brief_title>
  <official_title>Clinical Proteomics and Protein Therapeutics in Human Hypertension (BNP in Human Hypertension - Phase 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators working hypothesis is that human hypertension is in part due to a&#xD;
      derangement in the endocrine function of the heart - a primary or secondary mechanism -&#xD;
      resulting in a relative deficiency of the natriuretic peptides (NP). The remodeled&#xD;
      hypertensive heart could result in altered processing and degradation of B-type NP resulting&#xD;
      in altered molecular forms with decreased biological activity. The investigators further&#xD;
      hypothesized the chronic administration of BNP in subjects with hypertension, is feasible,&#xD;
      safe and will induce a sustained reduction in blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ongoing investigations by our laboratory group and others have established that the heart is&#xD;
      an endocrine organ as well as a pump. The heart synthesizes and secretes two peptide hormones&#xD;
      - atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) - that are endogenous&#xD;
      ligands for a particulate guanylyl cyclase receptor (NPR-A). Following receptor binding and&#xD;
      generation of its second messenger cGMP, the natriuretic peptides (NPs) mediate biological&#xD;
      actions which include natriuresis, inhibition of the renin-angiotensin system and&#xD;
      vasodilatation with local autocrine and paracrine actions in the heart to include inhibition&#xD;
      of fibrosis and enhancement of diastolic function.&#xD;
&#xD;
      Hypertension remains a global burden in cardiovascular disease leading to stroke, myocardial&#xD;
      infarction and heart failure. Its myocardial complications result from increased mechanical&#xD;
      load on the heart. Under physiological conditions of increased myocardial load and resulting&#xD;
      myocardial stretch, ANP and BNP synthesis and secretion occur contributing to maintenance of&#xD;
      optimal cardiorenal and blood pressure homeostasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The blood pressure will decrease with BNP injections</measure>
    <time_frame>during study intervention</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Hypertension Stage 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brain natriuretic peptide</intervention_name>
    <description>start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no-added salt diet</intervention_name>
    <description>instruction to reduce salt for one week prior to study</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Subjects with stage 1 hypertension (SBP: 140-159 mm Hg or DBP 90-99 mm Hg) If on&#xD;
             therapy, it must be stable for at least 1 month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congestive Heart Failure (any NYHA class).&#xD;
&#xD;
          -  EF &lt; 50%.&#xD;
&#xD;
          -  Myocardial infarction within 3 months of screening.&#xD;
&#xD;
          -  Unstable angina within 14 days of screening, or any evidence of myocardial ischemia.&#xD;
&#xD;
          -  Moderate to severe pulmonary hypertension.&#xD;
&#xD;
          -  Valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy,&#xD;
             constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active&#xD;
             myocarditis.&#xD;
&#xD;
          -  Sustained VT or V-fib within 14 days of screening.&#xD;
&#xD;
          -  Sustained Atrial Fibrillation.&#xD;
&#xD;
          -  Second or third degree AV block without a permanent cardiac pacemaker.&#xD;
&#xD;
          -  CVA within 3 months of screening, or other evidence of significantly compromised CNS&#xD;
             perfusion.&#xD;
&#xD;
          -  Total bilirubin of &gt;1.5 mg/dL or AST and ALT 1.5 times the upper limit of normal&#xD;
             range.&#xD;
&#xD;
          -  Renal insufficiency assessed by calculated GFR &lt; 60 ml/min (Cockroft-Gault equation).&#xD;
&#xD;
          -  Serum sodium of &lt; 125 mEq/dL or &gt; 160 mEq/dL.&#xD;
&#xD;
          -  Serum potassium of &lt; 3.5 mEq/dL or &gt; 5.0 mEq/dL.&#xD;
&#xD;
          -  Women taking hormonal contraceptives.&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 35.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

